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Abstract
Background: Umbilical cord blood provides a source of hematopoietic stem cells for transplantation with
immunological and availability advantages over conventional bone marrow sources. Limited cell numbers and
slower engraftment from umbilical cord blood units has led to the clinical development of immobilised Notch
ligand Delta-Like 1 to promote ex vivo expansion of a rapidly engrafting cell population. However, current
immobilisation methods are not simple to scale in a controlled manner.
Results: Delta-Like 1 was immobilised onto streptavidin coated magnetic particles via a heterobifunctionalised
polyethylene glycol linker molecule to provide an easily manipulated format of surface protein presentation. CD34+
enriched cord blood cells were treated with Delta-Like 1 immobilised particles, and immunophenotypic markers
measured to monitor population distributions using cluster identification, characterization, and regression software.
The amenability of the approach to scalability was evaluated in a micro-scale stirred tank bioreactor. Surface
concentration of Delta-Like 1 was well controlled used differing stoichiometric reagent ratios. Protein
immobilisation was a cost effective process and particles were efficiently removed from the final cell product.
Immobilised Delta-Like 1 is functional and stimulates qualitatively similar CD34hi, CD38lo, CD90lo, CD133hi, CD135hi
progenitor expansion in both static culture and scalable stirred culture platforms.
Conclusions: Immobilised Delta-Like 1 in this form has the potential to improve the manufacturing efficiency and
control of final ex vivo expanded cell product through compatibility with highly controlled and characterised
suspension culture systems.
Keywords: Cell culture, Ex vivo expansion, Delta-like 1, Hematopoietic progenitor cell, Immobilised, Manufacturing,
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Background
Hematopoietic stem cell (HSC) transplantation is an
effective therapy for numerous hematopoietic disorders.
HSCs are available from various human sources: mobilised
peripheral blood (MPB), bone marrow (BM), and umbil-
ical cord blood (UCB). Although all have shown clinical
efficacy, HSCs derived from UCB eliminates risk to the
donor, are readily available as a sustainable source, offer a
lower transmission rate of infectious and genetic diseases,
and are more tolerant of immunological mismatches com-
pared to those from other sources [1]. The immunological
properties significantly improve the likelihood of donor
matching and reduce the incidence of graft versus host
disease (GVHD) [2]. Successful transplantation relies
upon the function of long and short term repopulating
HSCs, as well as a short time to engraftment into the BM
to minimise post-transplant susceptibility to infection and
bleeding disorders. One of the key drawbacks of UCB as a
source is the inability to obtain sufficient numbers of
HSCs from a single cord for transplantation into the
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average adult patient; this contributes to prolonged phases
of neutropenia, thrombocytopenia and suboptimal en-
graftment into the recipient BM [3–7].
The ex vivo expansion of UCB cells is one way to
overcome the limited cell numbers available. Upon
expansion HSCs are capable of either self-renewal or
differentiation to lineage committed cells; an appropriate
balance in this expansion phase is required to produce a
cell population with the necessary engraftment charac-
teristics. Supportive conditions and factors for primitive
cell expansion have been identified, including the key
cytokines stem cell factor (SCF), flt3/flk2 ligand (FLT),
and thrombopoietin (TPO) [8–11]. However, such cyto-
kine mediated expansion methodologies have not shown
significant clinical improvement in time to engraftment
[12–14]. Co-culture with other cell types is another
approach being investigated by researchers to improve
expansion and lower the time to engraftment with good
success [15], however this method relies upon the
introduction of a contaminating cell type and presents
more challenges in downstream processing [16]. Factors
which generate a population that retains long term
repopulating ability and also boosts the progenitor cells
responsible for rapid engraftment, through various in-
trinsic signalling pathways, are being investigated clinic-
ally [13, 17, 18]. One candidate, the Notch pathway, is
well documented to have a modulatory effect on the dif-
ferentiation of stem cell systems including various effects
on HSC and hematopoietic progenitor proliferation and
commitment [19, 20]. Notch signalling is mediated by
interactions between transmembrane receptors, includ-
ing members of the Delta like (DL1, DL3, DL4) family
and their membrane bound ligand. Ex vivo expansion of
HSC progenitors in the presence of immobilised DL1
(iDL1) produces an approximate 100-fold greater in-
crease of CD34+ cells relative to a non-DL1 control [21].
These cells have enhanced repopulating ability in a sub-
lethally irradiated mouse model, notably substantially
faster and higher levels of myeloid and lymphoid
engraftment [22].
A phase 1 clinical trial to identify whether CD34+
enriched UCB could be expanded in the presence of
immobilised DL1 to accelerate hematopoietic recovery re-
cently met its primary objective and was deemed safe [23].
The culture process utilised X-fold™ tissue culture bags
and Nunc flasks [24]. Infused CD34+ number has been
identified as one of the best indicators for rapid
hematopoietic recovery [25]. Due to feedback from ma-
ture cells influencing lineage development during the ex-
pansion process [26], culture densities are kept relatively
low, typically below 5 × 105 mL−1. In order to produce the
CD34+ cell numbers (2-5 × 106) reported large medium
volumes are required [27]. Furthermore, a non-mixed cul-
ture flask does not provide a scalable and homogenous
interaction between surface presented ligand and cells.
Given the reported dose-dependence of engraftment on
DL-1 exposure, such controllable interaction would be ne-
cessary for process reproducibility across scales [21].
Herein we describe the controlled immobilisation of
biotinylated DL-1 onto streptavidin coated magnetic
particles to enable incorporation into a highly controlled
and volume scalable suspension culture system. The
magnetic nature allows for the removal of the particles
from ex vivo culture vessels at specific time points, inde-
pendent of other medium components, enabling particle
recycling through medium exchange. Further, DL1
remained functional upon immobilisation and during
culture agitation, and exhibited a controllable response
via pronounced retention of progenitor cells in culture.
Methods
iDL1 particle preparation
iDL1 particles were produced using one of two routes
described as forward or reverse. Forward: lyophilised
carrier free DL1 (R and D systems, Abingdon, UK) was
suspended at 1 μM (unless otherwise stated) in either
sterile PBS or anhydrous DMSO. Biotin polyethylene
glycol (PEG) N-Hydroxysuccinimide (NHS), MW 2000,
(NANOCS, New York, USA) was suspended in anhyd-
rous DMSO at the required concentration for the
individual experiment being carried out. Equal volumes
of DL1 and heterobifunctionalised PEG molecule were
homogenised in an Eppendorf LoBind microcentrifuge
tube and incubated at room temperature for 2 h (unless
otherwise stated). MagnaLink Steptavidin Magnetic
Beads (Nominal mean bead diameter: 3 μm, Solulink,
San Diego, USA) were prepared by thoroughly mixing
the stock solution, aliquoting the required particle num-
ber into a LoBind microcentrifuge tube and spinning the
particle suspension at 300 g for 8 min before removing
the supernatant. Biotinylated DL1 conjugates were sup-
plemented to the prepared 2.8 μm streptavidin coated
magnetic particles and incubated overnight at 4–8 °C
with constant mixing. Particles were washed 5 times
in 1 mL of PBS before DL1 quantification using flow
cytometry. Reverse: heterobifunctionalised PEG mole-
cules of various molecular weights, (2000, 5000 and
10,000) were suspended in anhydrous DMSO at a
concentration of 1 mM. Prepared MagnaLink Stepta-
vidin Magnetic Beads were added to the
heterobifunctionalised PEG molecule solution at ap-
proximately 2 × 105 particles μL−1 and incubated for
16 h unless otherwise stated. Particles were washed 5
times in 1 mL of anhydrous DMSO using a magnetic
plate rack (BioRad, California, USA) in order to re-
move unbound heterobifunctionalised PEG molecules.
Lyophilised carrier free DL1 was suspended at 1 μM,
unless otherwise stated, in either sterile PBS or
Moore et al. BMC Biotechnology  (2017) 17:65 Page 2 of 11
anhydrous DMSO and added directly to dry biotinylated
particles. Particles were incubated for 2 h, unless other-
wise stated, at room temperature with constant mixing.
After incubation particles were washed 5 times in 1 mL of
PBS before DL1 quantification using flow cytometry.
Quantification of DL1 immobilisation
2 × 105 magnetic particles were stained for 30 min at
room temperature with 5 μL of PE Mouse Anti-Human
Delta-Like Protein 1 (BD Biosciences, Oxford, UK) in
50 μL of stain buffer (ThermoFisher, London, UK). As a
negative control 2 × 105 magnetic particles were stained
in parallel with a PE IgG1 isotype control. After incuba-
tion particles were washed once with PBS before being
resuspended in 100 μL of stain buffer for analysis.
Florescent reference standards (Quantum MESF; Bangs
Labs Inc., Indianapolis, USA) were used to determine
the mean mass of DL1 per particle using the net
geometric mean of fluorescent intensity.
Cell culture
Cells were obtained as research units from the Anthony
Nolan Cell Therapy Centre (ANCTC). ANCTC obtain
tissue with informed consent and supply for specific
projects approved by their board under their generic
research tissue bank ethics. CD34+ enriched umbilical
cord-derived cells were obtained from 20 pooled UCB
mononuclear cells (MNCs) via positive selection using
CD34 MicroParticle Kit (MACS; Miltenyi Biotec,
Bergisch Gladbach, Germany). The CD34+ percentage of
enriched cells ranged from 92% to 97% post thaw as
assessed by flow cytometry. Isolated cells were cryopre-
served prior to experiments. Full phenotypic character-
isation post thaw can be found in Additional file 1. Cells
were cultured in Iscove’s modified Dulbecco’s medium
with GlutaMAX-I (Invitrogen, Paisley, UK) supple-
mented with 20% (v/v) BIT 9500 Serum Substitute
(Stemcell Technologies, Vancouver, Canada), 2% (v/v)
GlutaMAX (ThermoFisher) and cytokines known to
support HSC expansion, 100 ngmL−1 Stem Cell Factor
(SCF), Fms Related Tyrosine Kinase 3 (FLT3) and 50
ngmL−1 Thrombopoietin (TPO) (R and D Systems) [26].
Cells were seeded at 1 × 105 mL−1 and were reset back
to initial seeding density every 3 days through centrifu-
gation and re-suspension of cells in a 1:1 replacement of
spent medium:fresh medium, cytokines were added at
2× concentration in fresh medium to replace degraded
cytokines in the spent fraction. iDL1 particles were
added at time 0 h and retained in each treated sample
during medium exchange using a magnet. To control for
any effects of soluble DL1 or blank particles three differ-
ent controls were included: untreated, soluble DL1 and
blank particles. Cells within the untreated control group
were expanded devoid of DL1 or particles. Cells within
the soluble DL1 control group were treated with 50 ng/
mL of DL1, equivalent to the highest concentration
present in the treatment group. Cells with in the blank
particle group were treated with particles exclusive of
DL1, again at equivalent levels with the highest concen-
tration present in the treatment group. For static
conditions the number of biological replicates totalled
five, (n = 5) for the bioreactor conditions three biological
replicates were performed (n = 3). Expansion data was
interrogated for outliers using a Grubbs’ test. Outliers
were not included in the data analysis.
Bioreactor setup and maintenance
The ambr® bioreactor (TAP Biosystems, Royston UK) is
a scaled-down version of a classic stirred tank bioreactor
operating at micro-scale (10–15 mL), using multiple
disposable micro-bioreactors, with individual, auto-
mated, online monitoring and control of pH, oxygen
gassing, temperature and stir rate. The system has been
validated for 2 L scale-up equivalence [28]. Before cell
defrost, ambr® vessels were loaded with 14 mL of
medium and stabilised for temperature (37 °C), oxygen
delivery (atmospheric) and pH (7.4). Culture pH was
maintained by automated sodium bicarbonate (20 μL of
1 molL−1 solution: Sigma-Aldrich) additions at 2 h inter-
vals (if required) and regulated carbon dioxide gassing.
Impeller speed was 450 rpm, experimentally determined
as the slowest speed to keep particles in a homogenous
suspension [29, 30].
Cell phenotyping
The antigenic phenotype of UCB cells was assessed be-
fore and during ex vivo expansion. Approximately
1 × 105 cells per test were incubated with the required
antibody panel as per manufacturer’s instructions for
30 min at room temperature. All antibodies were
preconjugated and monoclonal. Progenitor panel: CD34-
PerCP-Vio700, CD38-FITC, CD45RA-VioGreen, CD90-
APC-Vio770, CD133-APC, CD135-PE-Vio770 (Miltenyi
Biotech) and CD33-PE (BD Biosciences). Mature stage
myeloid panel: CD13-APC, CD14-PE, CD15-VioGreen,
CD34-PerCP-Vio700, CD33-APC-Vio770, CD38-FITC,
CD123-VioBlue (Miltenyi Biotech). Analysis was con-
ducted with CITRUS (cluster identification, characterisa-
tion and regression) software [31]. The software uses a
regularized supervised learning algorithm to determine
the populations and features of the samples being ana-
lysed in a correlative manner. The results of a CITRUS
run are clusters (populations) that differentiate the ob-
served endpoint of the samples, and the features (relative
population abundance or median expression of a func-
tional marker) of the clusters that are responsible. All
CITRUS analyses were conducted using a Significance
Analysis of Microarrays (SAM) association model and a
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minimum cluster size of 4%, at least 5000 events from
each sample were included for the analysis.
Statistics
One-way ANOVA (analysis of variance) with post-hoc
Tukey HSD (honestly significant difference) test calcula-
tor for comparing multiple treatments was used to
conduct statistical analysis. All values are reported as the
mean ± SD. Values were considered statistical significant
for P < 0.05.
Results
Optimal conditions for the immobilisation of Delta-like 1
The synthesis of an immobilised ligand complex using
streptavidin/biotin interactions can take place via two
discreet pathways: attaching the heterobifunctionalised
PEG molecule to the protein followed by incubation with
the particle (forward), or attaching the heterobifunctiona-
lised PEG molecule to the streptavidin particle followed
by incubation with the protein (reverse) (Fig. 1a). Further,
solvent choice can heavily influence the dissolution and
reaction of many protein reagents [32]. In order to identify
the conditions which led to maximum DL1 immobilisa-
tion the sequence of reaction steps and the solvent, PBS
or DMSO, in which the protein was dissolved, were evalu-
ated. It was observed that DL1 was immobilised at highest
levels when dissolved in PBS and processed via the reverse
reaction pathway (Fig. 1b). However, the solvent and reac-
tion sequence were non-independent; the outcome of the
reverse reaction was highly sensitive to solvent whereas
the forward reaction was not. This is likely to be due to
the different reaction sequences undergoing differing
levels of hydrolytic degradation of the NHS group and/or
protein denaturing in DMSO. The previously identified
most effective immobilisation pathway (reverse/PBS path-
way) was evaluated at each step for effect of reaction times
upon protein immobilisation. Maximal binding for the
first stage of the reaction, between the streptavidin coated
particle and heterobifunctionalised PEG molecule, oc-
curred rapidly with no additional binding observed after
4 h (Fig. 1c). The second stage of the process, the reaction
between the NHS group of the heterobifunctionalised
PEG molecule and primary amines present in DL1, was
also rapid with no significant increase in binding observed
after 30 min incubation (Fig. 1d).
Factors controlling surface concentration of Delta-like 1
It is known that certain proteins require particular
spatio-temporal presentation with respect to their
receptors to elicit specific cellular responses [33]. Planar
surface iDL1 concentration can be varied in order to
quantitatively regulate the induction of Notch signalling
which in turn differentially affects HSC lineage commit-
ment [22]. We therefore explored methodological
control of the concentration of iDL1 presented on the
particle surface. Although the reverse pathway was
favourable for maximum DL1 immobilisation, both
forward and reverse have the potential to control DL1
surface concentration. In the forward pathway increasing
the concentration of the heterobifunctionalised PEG
molecule in excess of DL1 lysine residues would be
anticipated to lead to unreacted NHS moieties. Hetero-
bifunctionalised PEG molecules not bound to DL1
would subsequently reduce binding of protein to the
particles via the competitive blanking of streptavidin. In
the reverse case, increasing the DL1 concentration
during synthesis would favour reaction of NHS with
protein relative to hydrolytic degradation and therefore
reduce the level of non-protein bound biotin-PEG avail-
able to blank the particles. In accordance with this, the
molar ratio of heterobifunctionalised PEG molecule:DL1
primary amine in the forward synthetic pathway signifi-
cantly influenced the concentration of iDL1; binding was
highest when the heterobifunctionalised PEG molecule
concentration was matched to the binding sites in the pro-
tein and fell sharply either side (Fig. 2a). Using the reverse
pathway it was possible to alter the amount of iDL1 by
simply altering the concentration of DL1 in the second
step of the reaction pathway (Fig. 2b). The final factor of
control investigated was the PEG length within the het-
erobifunctionalised PEG molecule. It was observed that an
increase in PEG length resulted in a reduction of iDL1,
presumably due to stearic hindrance (Fig. 2c).
Investigating manufacturing challenges of the use of
immobilised Delta-like 1
For immobilised proteins to be considered as an alternative
to soluble the immobilisation process must be cost effective
and the particles efficiently removed from the cell product
in downstream processing. To determine the level of
protein utilisation during the process, DL1 concentration in
the supernatant was measured before and after immobilisa-
tion. Protein immobilisation was found to be highly
efficient at defined particle:protein concentration ratios
(Fig. 3a), with up to 96% of the protein immobilised. It is
also important for ancillary materials to be easily and
reliably removable from any cell therapy product to aid
with regulatory approval [16]. Further, efficient removal will
enable simple exploration of alternative temporal exposure
to DL1 in future studies, and process control, independent
of other media elements. We therefore explored the condi-
tions required to remove the magnetic particles from HSC
culture. MACS® columns were utilised to successfully
remove magnetic particles from the cell product at the end
of the culture period. Magnetic particle levels were reduced
to 0.40% of the original concentration, as measured by flow
cytometry, with minimal cell loss (<1%) and no impact on
cell viability (Fig. 3b).
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Functionality of immobilised Delta-like 1 in static culture
iDL1 particles were added to UCB derived CD34+
enriched HSC culture in order to evaluate whether the
immobilised ligand complexes retained functionality to
retain progenitor cells during expansion. Particles and
cells remained in single suspension, with less than 0.1%
of cells forming aggregates as assessed by eye at 20× and
40× magnification (Additional file 2). Cell viability was
not impacted by treatment type, with cell viability
remaining above 97% throughout the culture period.
The fold expansion of the viable cell population ranged
between 310 and 563, the bead only control showed a
significant increase in expansion over the other treat-
ment types (p < 0.05). HSC progenitor and myeloid
lineage was assessed using flow cytometry to measure
the cell surface antigen expression of CD33, CD34,
CD38, CD45RA, CD90, CD133, CD135, CD13, CD14,
CD15, CD123. A computational approach, cluster
identification, characterisation and regression (CITRUS),
was applied to analyse flow cytometry data. CITRUS
overcomes a number of limitations of conventional
approaches to analysis and visualisation of multi-
dimensional flow data such as subjective user input,
labour intensity and requirement for prior knowledge or
assumptions of the biological system [31]. CITRUS orga-
nises cells into statistically distinct populations based on
clustering of marker expression and generates a 2D
phenotypic tree diagram based on phenotypic proximity
of populations. Analysis of data via this methodology re-
sults in a cluster tree for each of the clustering markers,
a (i)
a (ii)
b
c
d
Fig. 1 Delta-Like 1 can be reliably biotinylated and immobilised onto streptavidin coated magnetic micro particles. DL1 can be immobilised
using two distinct reaction pathways, a(i) forward, and a(ii) reverse. In the forward pathway DL1 primary amines first react with the NHS
functionality of the heterobifunctionalised PEG molecule. Once reacted, streptavidin coated magnetic particles are added allowing the biotin
functionality to bind with the streptavidin, resulting in iDL1. In the reverse pathway the heterobifunctionalised PEG molecule first reacts with the
streptavidin coated particle, the DL1 is then added and reacts with the NHS functionality to produce iDL1 (n = 3). b DL1 could be immobilised
via both pathways, the forward pathway demonstrated no effect of the DL1 solvent. The reverse pathway immobilised most DL1 per particle
when DL1 was dissolved in PBS (n = 3). c Optimisation of the reverse pathway for maximum DL1 immobilisation demonstrated a rapid saturation
of binding between streptavidin and the heterobifunctionalised PEG molecule during the first stage of the synthesis (n = 3) and d a 2 h optimal
incubation time for the second stage (n = 3)
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five of the clustering markers which contribute to pro-
genitor analysis are shown (Fig. 4a). Evaluation at day 6
and day 12 of the culture period showed consistent bias
in the percentage of cells within progenitor clusters,
denoted by CD34hiCD38negCD90negCD133hiCD135hi
(Fig. 4b, c) [34–37]. Cells treated with high levels of
iDL1 had significantly higher levels of progenitor cells at
both day 6 and 12 when compared to the three control
conditions. It was further observed that at the end of the
culture period (day 12) cells treated with all three levels
of iDL1 had significantly more cells in the progenitor
nodes than the untreated and soluble DL1 controls in a
concentration dependant manner. Further analysis on
day 12 of more mature surface antigens [21, 22] identi-
fied a significant decrease in CD14hi (Fig. 4d, e) and
CD15hi (Fig. 4f, g) cells when treated with iDL1 com-
pared with control treatments again in a dose dependent
manner. The dose dependent nature of the effect along-
side the consistent higher progenitor cell phenotype with
decreased mature antigen expression when cells are
treated with iDL1 demonstrates the ability of particle
presented DL1 to retain progenitor cell output.
Functionality of immobilised Delta-like 1 in stirred
bioreactor
Demonstration that iDL1 could similarly skew the
lineage output of CD34+ enriched cells in favour of an
earlier progenitor population in a stirred bioreactor was
important to show potential for scalable and controlled
application. CD34+ enriched cells cultured with iDL1 in
the stirred reactor again showed no proliferative disad-
vantage relative to the three controls. Again cell viability
was not impacted by treatment type, with cell viability
remaining above 95% throughout the culture period.
Total cell fold expansion showed no significant differ-
ence between treatment groups (range 142–177 fold).
Cells were analysed at the end of the culture period
using the same CITRUS analysis (Fig. 5a). As observed
in static culture, cells treated with iDL1 contained sig-
nificantly more progenitor cells than the three controls.
Further analysis of more mature surface antigens showed
no effect on CD14 but did again significantly decrease
the level of cells expressing CD15hi (Fig. 5c, d). Finally,
in order to test the longevity of iDL1 particles in a
stirred culture platform, particles were quantified daily
for their DL1 surface concentration throughout the
culture period. A fitted exponential decay model gave a
half-life of approximately 490 h (R2 = 67%).
Discussion
The role of Notch signalling in the expansion of HSCs,
and the potential for therapeutic application, has been
widely reported. Notch mediated expansion of UCB
progenitor cells results in significant proliferation of
a
b
c
Fig. 2 Surface concentration of immobilised Delta-Like 1 can be
controlled during particle synthesis. a Using the forward reaction pathway
it is possible to control the presentation of DL1 by regulating the ratio of
the heterobifunctionalised PEG molecule to the number of primary amine
groups present in DL1 (n = 3). b Using the reverse synthetic pathway, DL1
immobilisation increases with increasing DL1 concentration in the second
stage of the process (n = 3). c The use of increased PEG chain lengths
within the heterofunctionalised biotin molecule results in a reduction in
DL1 immobilisation using the reverse synthetic method (n = 3)
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precursor cells capable of rapid multi-lineage in vivo
NOD/SCID reconstitution [22]. However, efficient
Notch signalling in HSCs requires immobilisation of a
Notch ligand DL1 and in current protocols this immo-
bilisation is achieved on planar cell culture plastic [38].
The requirement for surface presented ligand compli-
cates simple application of suspension culture systems
and development of efficient and predictably scalable
methods. Micro-particles are an ideal carrier for immo-
bilised ligands as they offer a large surface area to
volume ratio and allow for control of localised concen-
tration and total culture concentration independently.
Furthermore they allow for the ligands to be removed
from the final cell product, removing the risk of inad-
vertent activation of undesired signalling pathways in
the recipient. They also have the benefit of being com-
patible with suspension manufacturing systems such as
stirred tank bioreactors, and scalable in such systems
with a consistent cell surface area to cell interaction.
Compatibility with well mixed stirred systems offers a
process developer a host of additional optimisation and
control opportunities such as precise gas, pH and
mechanical stress control.
Herein we have described the immobilisation of Notch
ligand DL1 onto the surface of magnetic micro particles.
DL1 surface concentration can be controlled via two
alternate methods, remains functional under stirred con-
ditions, and can be efficiently withdrawn from culture
using simple magnetic methods. In particular, the scale
of change of immobilised DL1 concentration achieved
via the reverse reaction in response to the change in
DL1 reaction concentration suggests this method would
offer reproducible control of immobilisation at the fg/
bead level. Further, the kinetics underlying this reaction
(different sensitivity of rate of hydrolysis of NHS to
temperature compared with NHS-protein reaction)
suggest efficiency of protein immobilisation should be
further tuneable by reaction temperature [39] i.e. colder
reaction temperatures would likely require lower protein
concentration for equivalent iDL1, reducing manufactur-
ing costs. The immobilisation process was demonstrated
to be highly economical with 96% of the input protein
immobilised. The efficiency of particle removal must be
considered during downstream processing, as a high loss
in cell yield would impact the feasibility of such ap-
proach. We demonstrated the particles can be effectively
a c 
b (ii) b (i) 
Cells
Particles
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Forward Scatter
Fig. 3 Investigating manufacturing challenges of the use of immobilised Delta-Like 1. Efficacy of the immobilisation process was evaluated using an
ELISA immunoassay. a Efficacy was dependent on the number of particles generated, with up to 96% of the protein immobilised (n = 3). Removal of
magnetic particles was evaluated by flow cytometry. b Voltage setting and gating was optimised to assess particle number in culture (i) and after
removal from culture (ii), c removal of magnetic particles from cells at the end of the culture period was evaluated, MACS® columns removed 99.6% of
particles with minimal cell loss (<1%) (n = 6)
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Fig. 4 (See legend on next page.)
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removed at the end of the expansion period with
minimal cell loss and no impact of cell viability.
Physical forces can influence how receptors transduce
signals [40]. The generally observed lack of functionality
of Notch ligands in soluble form is hypothesised to be
due to a mechanotransduction model of receptor activa-
tion [41]. Immobilised DL1 particles were functional.
Cells treated with high levels of iDL1 contained a signifi-
cantly higher percentage of progenitor cells compared to
the three controls in both static and stirred culture
platforms. Additionally iDL1 performed in a concentra-
tion dependent fashion on progenitor retention and the
suppression of cells expressing more mature surface
antigens.
(See figure on previous page.)
Fig. 4 Immobilised Delta-Like 1 can induce skewed lineage output of hematopoietic progenitor cells in static culture. CD34+ enriched cells (95% CD34+)
were cultured with iDL1 at three concentrations alongside three controls: untreated, soluble DL1 and blank particles only (n = 5). a FCS files were uploaded
into Cytobank and CITRUS cluster trees derived, clustering on CD34, CD33, CD38, CD45ra, CD90, CD133 and CD135 marker intensities. Cluster trees of
CD34, CD38, CD90, CD133 and CD135 are shown, identifying the progenitor nodes defined phenotypically as CD34hiCD38negCD90negCD133hiCD135hi. b
Progenitor nodes (identified in 4A) were evaluated for their percentage abundance at day 6 (i) and day 12 (ii), cells cultured with high levels of iDL1
contained a significantly higher percentage of progenitor cells compared to all controls. All concentrations of iDL1 significantly improved progenitor
abundance compared with untreated and soluble DL1 controls at day 12. Further phenotypic analysis was undertaken at day 12 to evaluate the expression
of more mature surface markers. FCS files were uploaded into Cytobank and CITRUS cluster trees derived, clustering on CD13, CD14, CD15, CD24, CD33,
CD38 and CD123 marker intensities. c Cluster tree of CD14 expression, the parent CD14hi node was identified. d Evaluation of percentage abundance
within the parent CD14hi node at day 12 identified culture with high and medium levels of iDL1 resulted in significantly less mature CD14hi cells compared
to all controls. e Cluster tree of CD15 expression, the parent CD15hi node was identified. (F) Evaluation of percentage abundance within the parent CD15hi
node at day 12 identified culture with high levels of iDL1 resulted in significantly less mature CD15hi cells compared to all controls. All concentrations of
iDL1 significantly decreased CD15hi abundance compared with untreated and soluble DL1 controls. Values were considered (*) statistically significant for
P < 0.05, (**) very statistically significant for P < 0.01
a b
c d
Fig. 5 Immobilised Delta-Like 1 induces the same lineage skewing of hematopoietic progenitor cells in stirred bioreactor systems. CD34+ enriched
cells (95% CD34+) were cultured with iDL1, alongside untreated, soluble DL1 and blank particles as controls, in a mechanically agitated suspension
bioreactor (n = 3). a As previously shown in the static platform, FCS files were uploaded into Cytobank and CITRUS cluster trees derived, clustering on
CD34, CD33, CD38, CD45ra, CD90, CD133 and CD135 marker intensities. Cluster trees of CD34, CD38, CD90, CD133 and CD135 are shown, identifying
the progenitor node defined phenotypically as CD34hiCD38negCD90negCD133hiCD135hi. b The addition of iDL1 to CD34+ enriched cells in a stirred
culture system led to the same trend in lineage skewing previously identified in static. Evaluation of the percentage abundance within the progenitor
node at day 12 identified high levels of iDL1 resulted in significantly more progenitor cells compared to all controls. c Cluster tree of CD15 expression,
the parent CD15hi node was identified. d Evaluation of percentage abundance within the parent CD15hi node at day 12 identified, as in the static
platform, culture with high levels of iDL1 resulted in significantly less mature CD15hi cells compared to all controls. Values were considered (*)
statistically significant for P < 0.05
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Laboratory to laboratory comparisons of phenotypic
changes measured by flow cytometry are challenging
due to subjectivity in analysis [42]. The use of CITRUS
software to identify statistically distinct populations
based on cell expression of two different 7 antigen
marker panels, progenitor and myeloid, removed any
subjectivity in cell gating and did not necessitate any
pre-conception on behalf of the investigators of popula-
tions that would be changed by experimental conditions.
CITRUS was effective for tracking populations across
time and the sensitivity inherent in relatively high sub-
division of the populations facilitated early detection of
the impact of culturing cells in the presence of iDL1.
Conclusions
The Notch pathway can be used in a clinically compliant
manner to generate a safe and potentially efficacious cell
therapy product [23]. The approach discussed has the
potential to improve the controlled scalability (in
particular volume to surface area) and cell fate control
of ex vivo expansion of HSCs for clinical use. It further
has the potential for application with other protein
targets important in hematopoietic cell expansion such
as Jagged 1/2, Wnt ligands and integrins [43]. In this
regard the methodology potentially provides an oppor-
tunity to recapitulate some wider surface presented
aspects of the stem cell niche and control a wider range
of biological outcomes in simple scalable systems.
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